Rapport Therapeutics

Biotech

rapportrx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
1 granted · 4 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2633NonExomics, Inc.—$200K
2634FruitVaccine Incorporation——
2635Amalgent Therapeutics, LLC—$200K
2636Rapport Therapeutics——
2637COSMICA Inc.—$200K
2638Ayala Pharmaceuticals, Inc.—$45M
2639YOUNG THERAPEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 5
  • Azabenzimidazoles And Their Use As Ampa Receptor Modulatorsapplication
  • Azabenzimidazoles And Their Use As Ampa Receptor Modulatorsgranted
  • Methods Of Usa Of Ampa Receptor Modulatorsapplication
  • Crystalline Forms Of 3-(7-CHLORO-1H-INDAZOL-5-YL)-2,5-BIS(TRIFLUOROMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINEapplication
  • Methods Of Use Of Ampa Receptor Modulatorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.